Next Article in Journal
Inpatient Burden and Mortality of Goodpasture’s Syndrome in the United States: Nationwide Inpatient Sample 2003–2014
Previous Article in Journal
Extracorporeal Shockwave Therapy Treatment in Upper Limb Diseases: A Systematic Review

Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy
Residency Program in Clinical Pathology and Clinical Biochemistry, Università degli Studi di Milano, 20133 Milan, Italy
Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Biometry and Epidemiology “G.A. Maccaro”, Università degli Studi di Milano, Via Vanzetti 5, 20133 Milan, Italy
Instrumentation Laboratory—A Werfen Company, R&D Department, Viale Monza 338, 20128 Milan, Italy
Service of Laboratory Medicine1-Clinical Pathology, IRCCS Policlinico San Donato, Piazza E. Malan, San Donato Milanese, 20097 Milan, Italy
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(2), 454;
Received: 10 January 2020 / Revised: 3 February 2020 / Accepted: 4 February 2020 / Published: 6 February 2020
(This article belongs to the Section Endocrinology & Metabolism)
A decline in metabolic health may take place before observing any alteration in the levels of the traditional metabolic markers. New indicators of metabolic derangement are therefore compelling. Irisin is a myokine with important metabolic functions. The role of irisin as a metabolic biomarker in humans has not been fully established yet. We quantified plasma irisin and esRAGE in 106 apparently healthy individuals and we performed a cluster analysis to evaluate their associations with metabolic profile. Plasma levels of various traditional markers of metabolic risk (i.e., glucose and lipid levels) were all within the ranges of normality. We identified two clusters of individuals. Compared to cluster 2, individuals in cluster 1 had higher irisin levels, a metabolic profile shifted toward the limits of the reference ranges and lower esRAGE levels. The traditional metabolic blood tests seem not to be enough to identify a metabolic decline early. Irisin increase and esRAGE decrease may reflect a metabolic derangement at the beginning of its development. The role of these molecules as early biomarkers of decline of metabolic health seems an interesting topic to be further explored. View Full-Text
Keywords: AGE; cardiometabolic risk; cRAGE; esRAGE; irisin; sRAGE AGE; cardiometabolic risk; cRAGE; esRAGE; irisin; sRAGE
Show Figures

Figure 1

MDPI and ACS Style

Dozio, E.; Vianello, E.; Sitzia, C.; Ambrogi, F.; Benedini, S.; Gorini, S.; Rampoldi, B.; Rigolini, R.; Tacchini, L.; Corsi Romanelli, M.M. Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health. J. Clin. Med. 2020, 9, 454.

AMA Style

Dozio E, Vianello E, Sitzia C, Ambrogi F, Benedini S, Gorini S, Rampoldi B, Rigolini R, Tacchini L, Corsi Romanelli MM. Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health. Journal of Clinical Medicine. 2020; 9(2):454.

Chicago/Turabian Style

Dozio, Elena, Elena Vianello, Clementina Sitzia, Federico Ambrogi, Stefano Benedini, Silvia Gorini, Benedetta Rampoldi, Roberta Rigolini, Lorenza Tacchini, and Massimiliano M. Corsi Romanelli 2020. "Circulating Irisin and esRAGE as Early Biomarkers of Decline of Metabolic Health" Journal of Clinical Medicine 9, no. 2: 454.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop